Iterum Therapeutics plc (ITRMF) FCF Margin (2017 - 2025)
Iterum Therapeutics (ITRMF) posted FCF Margin of 1912.56% for Q3 2025, up 95.3% on a QoQ basis from 40710.81% in Q1 2019.
Powered by 
Analysis
Iterum Therapeutics plc (ITRMF) FCF Margin (2017 - 2025) Analysis & Trends
Iterum Therapeutics has reported FCF Margin for 4 years, with the latest figure at 1912.56% in Q3 2025.
- On a quarterly basis, FCF Margin changed N/A year-over-year to 1912.56% in Q3 2025; TTM through Sep 2025 was 5007.18%, a N/A change from a year earlier, with the FY2019 full-year figure at 221475.68%, down 21257556.0% from the prior year.
- FCF Margin was 1912.56% for Q3 2025 at Iterum Therapeutics, up from 40710.81% in the prior quarter.
- The five-year high for FCF Margin was 1912.56% in Q3 2025, with the low at 1912.56% in Q3 2025.
Peer Set
Peer Comparison
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | -1,912.56% |
| Mar 31, 2019 | -40,710.81% |
| Dec 31, 2018 | -10,547.28% |
| Sep 30, 2018 | -10,831.10% |
| Jun 30, 2018 | -7,006.49% |
| Mar 31, 2018 | -6,105.24% |
| Dec 31, 2017 | -2,914.04% |
| Sep 30, 2017 | -3,515.72% |